FDA to review sBLA for epcoritamab plus R2 in relapsed or refractory FL
The US Food and Drug Administration (FDA) will review a supplemental Biologics License Application (sBLA) for epcoritamab combined with rituximab and lenalidomide (R2)
Lymphoma
Indolent B-Cell Lymphomas
Society Updates
The Society of Hematologic Oncology announces new half-day CME anemia in MDS/MPN workshop
Presession focused on MDS/MPN-related anemia. Participants can register for the presession and SOHO 2025 at soho.click/2025 . HOUSTON, April 3, 2025 /PRNewswire/ — The Society of Hematologic Oncology
Leukemia
Chronic Myeloid Leukemia
‘Remarkable’ tolerability observed with asciminib in a heavily pretreated real-world CML-CP population
An Italian real-world study assessed the use of asciminib in a compassionate use setting in heavily pretreated patients with chronic-phase chronic myeloid leukemia
Lymphoma
Mantle Cell Lymphoma
China NMPA grants Breakthrough Therapy Designation for mesutoclax in MCL
The Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation for mesutoclax for the
Myelodysplastic Syndromes
FDA grants Orphan Drug Designation for bexmarilimab in MDS
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for bexmarilimab for the treatment of patients with myelodysplastic syndromes (MDS).
Leukemia
Acute Myeloid Leukemia
Triplet combination does not extend survival for patients with AML
A phase 1b/2 study found that the combination of azacitidine, venetoclax, and magrolimab was safe for the treatment of acute myeloid leukemia (AML),
Lymphoma
Novel cell therapy approach shows ‘preliminary’ safety and efficacy in lymphoma
Cord blood-derived natural killer (NK) cells pre-complexed with AFM13, a CD30/CD16A bispecific antibody, resulted in 2-year event-free and overall survival rates of 26.2%
2025 AACR Annual Meeting
CD38 plays critical role in multiple myeloma progression
A mouse model confirmed the aggressive nature of CD38 expression in multiple myeloma (MM), which induces widespread metastasis, extensive bone degradation, renal involvement,
2025 AACR Annual Meeting
Off-the-shelf CAR NK-cell therapy shows promise for relapsed or refractory AML
A study presented at the American Association for Cancer Research Annual Meeting 2025 found that the investigational chimeric antigen receptor (CAR) therapy SENTI-202
Meeting News
Meetings / Conferences
2025 AACR Annual Meeting
AACR honors Larry Saltzman with 2025 Distinguished Public Service Award
The American Association for Cancer Research (AACR) has named Larry Saltzman, MD, a recipient of the 2025 Distinguished Public Service Award for his